TCGA-AR-A1AU-01A-11R-A12P-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 96
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.480
- HEDGEHOG_SIGNALING+0.410
- ESTROGEN_RESPONSE_LATE+0.400
- HYPOXIA+0.390
- MYOGENESIS+0.370
- TNFA_SIGNALING_VIA_NFKB+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- UV_RESPONSE_DN+0.330
- APICAL_JUNCTION+0.300
- MITOTIC_SPINDLE+0.270
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.430
- INTERFERON_ALPHA_RESPONSE-0.420
- OXIDATIVE_PHOSPHORYLATION-0.410
- INTERFERON_GAMMA_RESPONSE-0.390
- DNA_REPAIR-0.350
- E2F_TARGETS-0.340
- NOTCH_SIGNALING-0.250
- G2M_CHECKPOINT-0.140
- MYC_TARGETS_V1-0.120
- MTORC1_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 563e85fb-9532-4d69-a1b5-2bc77f237b77 | — | — | 0.792 |
| 2 | MNG119 | — | — | 0.787 |
| 3 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.778 |
| 4 | MNG528 | — | — | 0.772 |
| 5 | MNG115 | — | — | 0.770 |
| 6 | SRR8613758 | — | C | 0.764 |
| 7 | 20060260.Her2HRpos | — | A | 0.756 |
| 8 | de751aae-bc7a-4d70-9d06-4417be4facae | — | — | 0.751 |
| 9 | 20030016.LumA | — | B | 0.745 |
| 10 | SRR8613716 | — | C | 0.738 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.480 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| HYPOXIA | 0.390 | Idelalisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |